Agilent Technologies LSCA - Our measure is your success
clear
white
clear
white
clear

Press Release 

white
clear clear clear clear clear

grey1
Literature Library
Technical Support
Education & Events

grey1
Editorial Contacts PRCA08059 
Stuart Matlow 
+1 408 553 7191 
stuart_matlow@agilent.com 
Agilent Technologies Delivers Simpler Workflow with miRNA Microarray Labeling and Hybridization Kit 
SANTA CLARA,CA. , 7/29/2008  --

Agilent Technologies Inc. (NYSE: A) today introduced a new labeling and hybridization kit that simplifies the protocol for running miRNA profiling experiments on Agilent oligonucleotide microarrays.

The new kit, scheduled to ship in late July, contains all the reagents and buffer needed to label and hybridize 24 miRNA microarray experiments. Agilent's microarray-based tools for studying miRNAs combine a unique direct labeling method with innovative probe design. The result is a robust, highly sensitive platform that allows broad insight into expression and regulation of all known human, mouse and rat miRNAs. The system's dynamic range spans greater than 5 logs for comprehensive miRNA expression profiling, and sample input is only 100 nanograms.

"We continue to invest in the miRNA platform, and this second-generation kit is the latest example of this emphasis at Agilent," said Sangita Parikh, Agilent miRNA product manager. "In the year since we launched miRNA microarray products, the platform has achieved enthusiastic acceptance, and this is part of Agilent's ongoing strategy to drive growth in emerging microarray applications."

The following publication is an example of how researchers are using the Agilent miRNA microarray platform:

miRNAs indicate uveal melanoma severity

Researchers at the Washington University in St. Louis used Agilent miRNA microarrays to profile uveal melanomas, the second most common form of melanoma. Lori A. Worley, Meghan D. Long, Michael D. Onken and J. William Harbor published an article in the journal Melanoma Research (June 2008, vol. 18, no. 3), finding that miRNA gene expression signatures are good predictors of these melanomas' potential to cause death by metastasizing.

Agilent miRNA microarrays are configured with eight experiments per standard 1 in. x 3 in. slide, and three slides are included in each kit. This multiplex configuration minimizes cost-per-experiment in terms of purchase price, handling and reagents. Each experiment requires just 100 nanograms total RNA input per labeling reaction.

For more information, please visit www.opengenomics.com.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent had net revenues of $5.4 billion in fiscal 2007. Information about Agilent is available on the Web at www.agilent.com.

grey1
related_bottom_left clear clear clear
clear clear
grey2